期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

腹腔免疫化疗对晚期结肠癌癌性腹水患者IL-6及IL-10影响 被引量：2

The Effects of Intraperitoneal Immunochemotherapy on IL - 6 and IL - 10 Level in Patients with Advanced Colon Cancer with Ascites
下载PDF
导出
摘要 目的:探讨腹腔内免疫化疗前后晚期结肠癌癌性腹水患者血清IL-6及IL-10水平的变化及其意义。方法:采用酶联免疫法测定治疗前、治疗后1周及治疗后4周患者外周血清中IL-6及IL-10水平,并与正常对照组比较。结果:晚期结肠癌癌性腹水患者血清IL-6及IL-10水平较正常组明显升高。腹腔内免疫化疗治疗晚期结肠癌癌性腹水患者1周后大部分患者外周血清中IL-6及IL-10水平有所下降。四周后所有患者的IL-6及IL-10均有下降。且第1周后IL-6及IL-10水平有否变化与免疫化疗是否有效有明显关系。结论:腹腔内免疫化疗是治疗晚期结肠癌癌性腹水较为有效的方法。同时,早期监测外周血清中IL-6及IL-10水平对腹腔内免疫化疗的疗效有预测功能。 Objective: To study the effects of intraperitoneal immunochemotherapy on IL - 6 and IL - 10 level of advanced colon cancer patients with ascites. Methods: Before and after treatment, serum levels of IL -6 and IL -10 were observed by ELISA assay in 38 patients and compared with that in the control group. Results: The serum level of IL- 6 and IL- 10 of advanced colon cancer patients with ascites were higher than those of the control group. Serum level of IL - 6 and IL - 10 of most patients were decreased after first week of intraperitoneal immunochemotherapy and serum level of IL - 6 and IL - 10 were decreased in all patients after four weeks. And the change of serum level of IL - 6 and IL - 10 after first week treatment were correlated with effects of intraperitoeal immunochemotherapy. Conclusion: Intraperitoeal immunochemotherapy is an effective way for treat advanced colon cancer with ascites. Early monitoring serum level of IL - 6 and IL - 10 can predict the effect of intraperitoeal immunochemotherapy.
作者 金涌 朱金水 陈维雄 孙群 王如华 陈尼维
机构地区 上海市第六人民医院消化内科
出处 《中国临床医学》 2002年第5期519-520,共2页 Chinese Journal of Clinical Medicine
关键词 腹腔内免疫化疗 晚期结肠癌 癌性腹水 白介素6 白介素10 Intraperitoeal immunochemotherapy Late colon cancer Ascites of cancer Interleukin - 6 Interleukin - 10
分类号 R735.350.6 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献7

  • 1程中，国外临床，1991年，5卷，160页
  • 2陈峻青，实用外科杂志，1991年，11卷，426页
  • 3Pierre Jacquet M.D.,Andrew M. Averbach M.D.,Arvil D. Stephens B.S.,Paul H. Sugarbaker M.D.. Cancer recurrence following laparoscopic colectomy[J] 1995,Diseases of the Colon & Rectum(10):1110～1114
  • 4W. Graf,J. -E. Westlin,L. P?hlman,B. Glimelius. Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study[J] 1994,International Journal of Colorectal Disease(1):35～39
  • 5Dr. Paul H. Sugarbaker M.D.,Bo-Wei Zhu M.D.,Grace Banez Sese M.D.,Barry Shmookler M.D.. Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy[J] 1993,Diseases of the Colon & Rectum(4):323～329
  • 6Dr. Akio Yamaguchi M. D.,Yuuji Tsukioka M. D.,Sachio Fushida M. D.,Yoshiyuki Kurosaka M. D.,Masahiro Kanno M. D.,Yutaka Yonemura M. D.,Kouichi Miwa M.D.,Itsuo Miyazaki M. D.. Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers[J] 1992,Diseases of the Colon & Rectum(10):964～968
  • 7Dr. B. Nordlinger M.D.,Y. Panis M.D.,J. P. Puts M.D.,J. P. Herve M.D.,R. Delelo,F. Ballet M.D.. Experimental model of colon cancer: Recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy[J] 1991,Diseases of the Colon & Rectum(8):658～663

共引文献116

同被引文献21

  • 1Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class- Ⅰ , HLA class- Ⅱ and ICAM-1 molecules [J]. Int J Cancer, 1997, 71(4): 630～637.
  • 2Boyano MD, Garcia-Vazquez MD, Lopez Michelena T, et al.Soluble interleukin-2 receptor, intercellular adhesion molecule-1and interleukin-10 serum levels inpatients with melanoma[J]. Br J Cancer, 2000, 83(7): 847～852.
  • 3Galizia G, Lieto E, De Vita, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome [J].J Interferon Cytokine Res, 2002, 22(4): 473～482.
  • 4Sharma S, Stolina M, Lin Y, et al. T-cell derived IL-10 promotes lung cancer growth by suppressing both T-cell and APC function[J].J Immunol, 1999, 163(9): 5020～5028.
  • 5Knolle PA, Uhrig A, Hegenbarth S. IL-10 down-regulates Tcell activation by anti-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules [J]. Clin Exp Immunol, 1998, 114(3): 427～433.
  • 6Groux H, Bigler M, De Vries. Inhibitory and stimulatory effects of IL-10 on human CD8^+ T cell [J].J Immunol, 1998, 160(7):3188～3193.
  • 7Steinbrink K, Jonuleit H, Muller G, et al. Interleukin-10 treated human dendritic cells induce a melanoma antigen specific anergy in CD8+ T cell resulting in a failure to lyse tumor cells[J]. Blood,1999, 93(5): 1634～1642.
  • 8Elnemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape[J]. Int J Oncol, 2001, 18(1): 33～39.
  • 9Groux H,Bitgler M,De Vries.Inhibitory and sti-mulatory effects of IL-10 on human CD8+ T cell[J].J Immunol,1998,160(7):3188-3191.
  • 10Petersson M,Charo J,Salazar-Onfray F,et al.Con-stitutive UIL-10 production accounts for the high NK sensitivity,low MHC class I expression,and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK targe YAC-1[J].J Immunol,1998,161(15):2099-2105.

引证文献2

中国临床医学
2002年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部